These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Chromogenic in situ hybridization to detect EGFR gene copy number in cell blocks from fine-needle aspirates of non small cell lung carcinomas and lung metastases from colo-rectal cancer. Simone G; Mangia A; Malfettone A; Rubini V; Siciliano M; Di Benedetto A; Terrenato I; Novelli F; Mottolese M J Exp Clin Cancer Res; 2010 Sep; 29(1):125. PubMed ID: 20843314 [TBL] [Abstract][Full Text] [Related]
10. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer. Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995 [TBL] [Abstract][Full Text] [Related]
11. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Garm Spindler KL; Pallisgaard N; Rasmussen AA; Lindebjerg J; Andersen RF; Crüger D; Jakobsen A Ann Oncol; 2009 May; 20(5):879-84. PubMed ID: 19179548 [TBL] [Abstract][Full Text] [Related]
12. Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. Moretto R; Cremolini C; Rossini D; Pietrantonio F; Battaglin F; Mennitto A; Bergamo F; Loupakis F; Marmorino F; Berenato R; Marsico VA; Caporale M; Antoniotti C; Masi G; Salvatore L; Borelli B; Fontanini G; Lonardi S; De Braud F; Falcone A Oncologist; 2016 Aug; 21(8):988-94. PubMed ID: 27382031 [TBL] [Abstract][Full Text] [Related]
13. EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis. Jiang Z; Li C; Li F; Wang X PLoS One; 2013; 8(2):e56205. PubMed ID: 23441167 [TBL] [Abstract][Full Text] [Related]
14. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299 [TBL] [Abstract][Full Text] [Related]
15. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. Razis E; Pentheroudakis G; Rigakos G; Bobos M; Kouvatseas G; Tzaida O; Makatsoris T; Papakostas P; Bai M; Goussia A; Samantas E; Papamichael D; Romanidou O; Efstratiou I; Tsolaki E; Psyrri A; De Roock W; Bafaloukos D; Klouvas G; Tejpar S; Kalogeras KT; Pectasides D; Fountzilas G J Cancer Res Clin Oncol; 2014 May; 140(5):737-48. PubMed ID: 24595598 [TBL] [Abstract][Full Text] [Related]
17. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573 [TBL] [Abstract][Full Text] [Related]
18. EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Loupakis F; Cremolini C; Fioravanti A; Orlandi P; Salvatore L; Masi G; Schirripa M; Di Desidero T; Antoniotti C; Canu B; Faviana P; Sensi E; Lupi C; Fontanini G; Basolo F; Di Paolo A; Danesi R; Falcone A; Bocci G Target Oncol; 2014 Sep; 9(3):205-14. PubMed ID: 23821377 [TBL] [Abstract][Full Text] [Related]
19. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Martin V; Landi L; Molinari F; Fountzilas G; Geva R; Riva A; Saletti P; De Dosso S; Spitale A; Tejpar S; Kalogeras KT; Mazzucchelli L; Frattini M; Cappuzzo F Br J Cancer; 2013 Feb; 108(3):668-75. PubMed ID: 23348520 [TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Personeni N; Fieuws S; Piessevaux H; De Hertogh G; De Schutter J; Biesmans B; De Roock W; Capoen A; Debiec-Rychter M; Van Laethem JL; Peeters M; Humblet Y; Van Cutsem E; Tejpar S Clin Cancer Res; 2008 Sep; 14(18):5869-76. PubMed ID: 18794099 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]